Search Results

There are 2074 results for: content related to: Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  1. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients

    Transplant Infectious Disease

    Volume 12, Issue 3, June 2010, Pages: 195–203, M.D. Pescovitz, R.B. Ettenger, C.F. Strife, J.R. Sherbotie, S.E. Thomas, S. McDiarmid, S. Bartosh, J. Ives, M.R. Bouw and J. Bucuvalas

    Version of Record online : 7 DEC 2009, DOI: 10.1111/j.1399-3062.2009.00478.x

  2. You have free access to this content
    Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir

    Liver Transplantation

    Volume 18, Issue 3, March 2012, Pages: 347–354, Ashley N. Bedel, Trina S. Hemmelgarn and Rohit Kohli

    Version of Record online : 24 FEB 2012, DOI: 10.1002/lt.22471

  3. You have free access to this content
    Valganciclovir: Recent Progress

    American Journal of Transplantation

    Volume 10, Issue 6, June 2010, Pages: 1359–1364, M. D. Pescovitz

    Version of Record online : 28 APR 2010, DOI: 10.1111/j.1600-6143.2010.03112.x

  4. You have free access to this content
    Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study

    International Journal of Cancer

    Volume 133, Issue 5, 1 September 2013, Pages: 1204–1213, Giuseppe Stragliotto, Afsar Rahbar, Nina Wolmer Solberg, Anders Lilja, Chato Taher, Abiel Orrego, Birgitta Bjurman, Charlotte Tammik, Petra Skarman, Inti Peredo and Cecilia Söderberg-Nauclér

    Version of Record online : 13 MAR 2013, DOI: 10.1002/ijc.28111

  5. You have free access to this content
    Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis

    American Journal of Transplantation

    Volume 10, Issue 9, September 2010, Pages: 2026–2032, I. Helanterä, L. Kyllönen, I. Lautenschlager, K. Salmela and P. Koskinen

    Version of Record online : 27 AUG 2010, DOI: 10.1111/j.1600-6143.2010.03225.x

  6. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2

    Journal of Pharmaceutical Sciences

    Volume 89, Issue 6, June 2000, Pages: 781–789, Mitsuru Sugawara, Wei Huang, You-Jun Fei, Frederick H. Leibach, Vadivel Ganapathy and Malliga E. Ganapathy

    Version of Record online : 20 JUN 2000, DOI: 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7

  7. Ganciclovir Population Pharmacokinetics in Neonates Following Intravenous Administration of Ganciclovir and Oral Administration of a Liquid Valganciclovir Formulation

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 6, June 2007, Pages: 867–872, E P Acosta, R C Brundage, J R King, P J Sánchez, S Sood, V Agrawal, J Homans, R F Jacobs, D Lang, J R Romero, J Griffin, G Cloud, R Whitley, D W Kimberlin and For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

    Version of Record online : 28 MAR 2007, DOI: 10.1038/sj.clpt.6100150

  8. You have free access to this content
    Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation

    Transplant International

    Volume 23, Issue 9, September 2010, Pages: 897–906, Francesca Leone, Ahmed Akl, Magali Giral, Jacques Dantal, Gilles Blancho, Jean-Paul Soulillou and Diego Cantarovich

    Version of Record online : 10 MAR 2010, DOI: 10.1111/j.1432-2277.2010.01073.x

  9. You have free access to this content
    Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients

    British Journal of Clinical Pharmacology

    Volume 78, Issue 2, August 2014, Pages: 343–352, Heather E. Vezina, Richard C. Brundage and Henry H. Balfour Jr

    Version of Record online : 21 JUL 2014, DOI: 10.1111/bcp.12343

  10. You have free access to this content
    Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation

    American Journal of Transplantation

    Volume 4, Issue 10, October 2004, Pages: 1635–1642, Martin R. Zamora, Mark R. Nicolls, Tony N. Hodges, Jane Marquesen, Todd Astor, Todd Grazia and David Weill

    Version of Record online : 20 JUL 2004, DOI: 10.1111/j.1600-6143.2004.00571.x

  11. You have free access to this content
    Polyfunctional Cytomegalovirus-Specific Immunity in Lung Transplant Recipients Receiving Valganciclovir Prophylaxis

    American Journal of Transplantation

    Volume 11, Issue 3, March 2011, Pages: 553–560, L. D. Snyder, R. Medinas, C. Chan, S. Sparks, W. A Davis, S. M. Palmer and K. J. Weinhold

    Version of Record online : 10 JAN 2011, DOI: 10.1111/j.1600-6143.2010.03405.x

  12. You have free access to this content
    Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

    American Journal of Transplantation

    Volume 4, Issue 4, April 2004, Pages: 611–620, Carlos Paya, Atul Humar, Ed Dominguez, Kenneth Washburn, Emily Blumberg, Barbara Alexander, Richard Freeman, Nigel Heaton, Mark D. Pescovitz and Valganciclovir Solid Organ Transplant Study Group

    Version of Record online : 25 FEB 2004, DOI: 10.1111/j.1600-6143.2004.00382.x

  13. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics

    Transplant Infectious Disease

    Volume 12, Issue 3, June 2010, Pages: 204–212, A. Caldés, S. Gil-Vernet, Y. Armendariz, H. Colom, L. Pou, J. Niubó, L. Lladó, J. Torras, N. Manito, G. Rufí and J.M. Grinyó

    Version of Record online : 9 DEC 2009, DOI: 10.1111/j.1399-3062.2009.00481.x

  14. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients

    Clinical Transplantation

    Volume 21, Issue 4, July/August 2007, Pages: 441–448, Federico Oppenheimer, Miguel Gonzalez-Molina and Marta Rubio

    Version of Record online : 30 JUN 2007, DOI: 10.1111/j.1399-0012.2007.00612.x

  15. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein–Barr virus IgG antibody titers

    Journal of Medical Virology

    Volume 84, Issue 12, December 2012, Pages: 1967–1974, Tessa Watt, Stephanie Oberfoell, Raymond Balise, Mitchell R. Lunn, Aroop K. Kar, Lindsey Merrihew, Munveer S. Bhangoo and José G. Montoya

    Version of Record online : 10 OCT 2012, DOI: 10.1002/jmv.23411

  16. You have free access to this content
    Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

    Intervention Review

    The Cochrane Library

    Elisabeth M Hodson, Maleeka Ladhani, Angela C Webster, Giovanni FM Strippoli and Jonathan C Craig

    Published Online : 28 FEB 2013, DOI: 10.1002/14651858.CD003774.pub4

  17. You have free access to this content
    Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review

    American Journal of Transplantation

    Volume 8, Issue 10, October 2008, Pages: 2111–2118, H-Y. Sun, M. M. Wagener and N. Singh

    Version of Record online : 16 SEP 2008, DOI: 10.1111/j.1600-6143.2008.02369.x

  18. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis

    Transplant Infectious Disease

    Volume 14, Issue 3, June 2012, Pages: 248–258, A.P. Wiita, N. Roubinian, Y. Khan, P.V. Chin-Hong, J.P. Singer, J.A. Golden and S. Miller

    Version of Record online : 5 MAR 2012, DOI: 10.1111/j.1399-3062.2012.00723.x

  19. You have free access to this content
    A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV-Seropositive Lung Transplant Recipients

    American Journal of Transplantation

    Volume 9, Issue 5, May 2009, Pages: 1134–1141, V. Monforte, C. Lopez, F. Santos, F. Zurbano, M. De La Torre, A. Sole, J. Gavalda, P. Ussetti, R. Lama, J. Cifrian, J. M. Borro, A. Pastor, O. Len, C. Bravo and A. Roman

    Version of Record online : 16 MAR 2009, DOI: 10.1111/j.1600-6143.2009.02574.x

  20. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation

    Pediatric Transplantation

    Volume 14, Issue 6, September 2010, Pages: 753–760, E. Lapidus-Krol, R. Shapiro, J. Amir, M. Davidovits, R. Steinberg, E. Mor and Y. Avitzur

    Version of Record online : 3 MAY 2010, DOI: 10.1111/j.1399-3046.2010.01330.x